Gabriele Cerrone

Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.

FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY.

Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Arna Therapeutics Ltd. is a British biotechnology company that focuses on research and experimental development. The private company was founded by Gabriele Marco Antonio Cerrone.

Gensignia Life Sciences, Inc. is a molecular diagnostics company that develops new molecular diagnosis techniques. The private company is based in San Diego, CA. The company was founded by Gabriele Marco Antonio Cerrone.

Rasna Therapeutics, Inc. operates as a development stage biotechnology company focused on the development of cancer drugs. It is focused primarily on the development of drug candidates for leukemia and lymphoma. The company was founded by Gabriele Marco Antonio Cerrone, Roberto Pellicciari and Brunangelo Falini in 2013 and is headquartered in San Diego, CA.

Founded in 2014, Gensignia IP Ltd. is a professional, scientific, and British technical services company. Part of Gensignia Life Sciences, Inc., the company is based in London, UK.

Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY.